[Atrial fibrillation in a patient with non-small-cell carcinoma of the lung in the course of paclitaxel therapy].
We report a clinical case of a patient with NSCLC who experienced an atrial fibrillation during paclitaxel infusion. Before chemotherapy, his cardiological function was normal. No cardiovascular and/or thyroid associated disease were previously reported. The patient did not receive any drugs with pro-arrhythmic effects. Incidence of cardiovascular toxicity in patients treated with paclitaxel is low, and does not justify strict cardiological monitoring otherwise deserved to patients with preexistent risk factors.
Dipartimento di Medicina Sperimentale, Università La Sapienza, Italia.
L
L
Moscetti
S
S
Ramponi
C
C
Maccaglia
P
P
Villanti
E
E
Cortesi
D001281:Atrial Fibrillation / Q000139:chemically induced*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*
D017239:Paclitaxel